ADOPT-lung trial: what clinicians have said so far
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
- NCT06284317 ↗
- Recruiting
- ETOP IBCSG Partners Foundation
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on ADOPT-lung (durvalumab in stage IIB-IIIB (N2) resectable NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 16 indexed sources
Automated from all 16 indexed sources (Dec 2024 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether adjuvant durvalumab adds benefit after neoadjuvant chemotherapy plus durvalumab, or neoadjuvant-only treatment suffices
- Whether patients without a pathologic complete response gain from adjuvant durvalumab while those with one do not
- Whether PD-L1-negative or higher-stage disease identifies who needs the adjuvant durvalumab phase
- Whether a further year of adjuvant durvalumab after surgery is needed or amounts to overtreatment
Indexed commentary on ADOPT-lung so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 11 posts on X, typically up to 48 once built | |
| 4 podcast episodes, typically up to 18 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Adjuvant durvalumab
- Arms
- Durvalumab · Experimental
- Observation · No intervention
- Enrollment
- 290 (estimated)
- Primary outcomes
- Disease-free survival (DFS)
- Sponsor
- ETOP IBCSG Partners Foundation with AstraZeneca
- Start
- Jan 15, 2025
- Primary completion
- Oct 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06284317 · updated Nov 6, 2026